Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004522 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 study, sponsored by SecuraBio.
- Completed
- Registry status
- Phase 3
- Development phase
- 319
- Enrollment target
NCT02004522 is a Phase 3 study that has completed, run by SecuraBio. The registered enrollment target is 319 participants.
The verdict
NCT02004522, a Phase 3 study, has completed, sponsored by SecuraBio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 319 participants
- Enrollment target
Study Summary
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
Interventions
- DRUG Duvelisib
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2013-11 |
| Est. Completion | 2021-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02004522
The ClinicalTrials.gov registry entry for NCT02004522 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 319 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SecuraBio, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Duvelisib is the first listed.
NCT02004522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02004522 about?
NCT02004522 is a clinical study titled "A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)". A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
What is the current status of trial NCT02004522?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 319 participants. The study started on 2013-11. Estimated completion is 2021-06.
What interventions are being tested in trial NCT02004522?
The interventions under investigation include: Duvelisib (DRUG), Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT02004522?
This trial is sponsored by SecuraBio, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.